Rachelle S. Doody, M.D., Ph.D.

Professor of Neurology
Effie Marie Cain Chair in Alzheimer's Disease Research

Clinical Service Area

Neurology

Specialty

Alzheimer's Disease
Memory Disorders

Board Certification

American Board of Psychiatry and Neurology, Neurology

Clinic Appointments

713-798-4734

Consult

713-798-4734

Medical School

Baylor College of Medicine, Houston, TX

Internship

Internal Medicine, McGill University Faculty of Medicine, Montreal, Quebec , Canada

Residency

Neurology, Baylor College of Medicine, Houston, TX

Clinical Interests

Alzheimer's disease, neurodegenerative dementias, Ischernic Vascular Dementia, memory loss, mild cognitive impairment

Clinic Location

Baylor Neurology
Smith Tower
6550 Fannin St., Suite 1801
Houston, TX 77030

Research Interests

Cognitive aspects of Alzheimer's disease, dementia, and aphasia. Alzheimer's Disease therapeutics and modeling of progression for clinical prognostication, validation of biological markers, and enhancing design of AD clinical trials.

Publications
Collapse All | Expand All

Doody RS. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease. Alzheimers Dement. 2009;5:133-6.
Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009;72:1555-61.
Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, et al. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009;5:85-92.
Na HR, Lee SH, Lee JS, Doody RS, Kim SY. Korean Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer's Disease. Dement Geriatr Cogn Disord. 2009;27:69-75.
Snyder PJ, Papp KV, Bartkowiak J, Jackson CE, Doody RS. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. Alzheimers Dement. 2009;5:122-4.
Doody RS. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development. Alzheimers Dement. 2008;4:S21-5.
Doody RS. Cholinesterase inhibitors and memantine: Best practices. CNS Spectr. 2008;13:34-5.
Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008;25:163-74.
Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372:207-15.
Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer?s disease. Alzheimers Dement. 2008;3:7-17.
Jack CR, Jr., Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008;29:1285-95.
Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008;4:145-53.
Kelly PA, Dyer CB, Pavlik V, Doody R, Jogerst G. Exploring self-neglect in older adults: preliminary findings of the self-neglect severity scale and next steps. J Am Geriatr Soc. 2008;56 Suppl 2:S253-60.
O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, Lupo PJ, Reisch JS, Doody R. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008;65:1091-5.
Yan JH, Rountree S, Massman P, Doody RS, Li H. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res. 2008;42:1203-12.
Atchison TB, Massman PJ, Doody RS. Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. Arch Clin Neuropsychol. 2007;22:99-107.
Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69:459-69.
Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007;69:1622-34.
Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS. Is functional decline necessary for a diagnosis of Alzheimer's disease? Dement Geriatr Cogn Disord. 2007;24:375-9.
Rountree SD, Waring SC, Chan WC, Lupo PJ, Darby EJ, Doody RS. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007;24:476-82.
Dyer CB, Kelly PA, Pavlik VN, Lee J, Doody RS, Regev T, Pickens S, Burnett J, Smith SM. The making of a self-neglect severity scale. J Elder Abuse Negl. 2006;18:13-23.
Fillit HM, Doody RS, Binaso K, Crooks GM, Ferris SH, Farlow MR, Leifer B, Mills C, Minkoff N, Orland B, Reichman WE, Salloway S. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006;4 Suppl A:S9-S24; quiz S25-S28.
Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006;10:417-29.
Pavlik VN, Doody RS, Massman PJ, Chan W. Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;22:367-77.
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006;63:49-54.
Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, Reisberg B, Schmitt FA. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006;20:S124-38.
Doody R, Pavlik V, Massman P, Kenan M, Yeh S, Powell S, Cooke N, Dyer C, Demirovic J, Waring S, Chan W. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord. 2005;20:198-208.
Doody RS. Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005;Suppl:14-20.
Graham DP, Kunik ME, Doody R, Snow AL. Self-reported awareness of performance in dementia. Brain Res Cogn Brain Res. 2005;25:144-52.
Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005;62:454-9.
Pavlik VN, Hyman DJ, Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 2005;24:42-50.
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379-88.
Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005;20:338-44.
Snow AL, Graham DP, Molinari VA, Orengo CA, Doody RS, Norris MP, Kunik ME. Factors affecting deficit awareness in persons with dementia. Dement Geriatr Cogn Disord. 2005;20:133-9.
Snow AL, Kunik ME, Molinari VA, Orengo CA, Doody R, Graham DP, Norris MP. Accuracy of self-reported depression in persons with dementia. J Am Geriatr Soc. 2005;53:389-96.
Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005;19:178-83.
Doody R, Wirth Y, Schmitt F, Mobius HJ. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;18:227-32.
Doody RS, Dunn JK, Huang E, Azher S, Kataki M. A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17:1-4.
Graham DP, Cully JA, Snow AL, Massman P, Doody R. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord. 2004;18:236-40.
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Jr., Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59-66.
Snow AL, Norris MP, Doody R, Molinari VA, Orengo CA, Kunik ME. Dementia Deficits Scale. Rating self-awareness of deficits. Alzheimer Dis Assoc Disord. 2004;18:22-31.
Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Jr., Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696-702.
Davis RN, Massman PJ, Doody RS. Effects of blood pressure on neuropsychological functioning in Alzheimer's disease. Arch Clin Neuropsychol. 2003;18:19-32.
Davis RN, Massman PJ, Doody RS. WAIS-R factor structure in Alzheimer's disease patients: a comparison of alternative models and an assessment of their generalizability. Psychol Aging. 2003;18:836-43.
Doody RS. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry. 2003;64 Suppl 9:11-7.
Doody RS. Update on Alzheimer drugs (donepezil). Neurologist. 2003;9:225-9.
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-41.
Smith RG, Roher AE, Appel SH, Doody RS, Killian JM, Corey-Bloom J, Sabbagh MN. Autonomic sudomotor dysfunction in Alzheimer's disease. Curr Med Chem ? Imun Endoc Metab Agents. 2003;3:77-84.
Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479-86.
Quinn J, Moore M, Benson DF, Clark CM, Doody R, Jagust W, Knopman D, Kaye JA. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology. 2002;58:433-7.
Weiner MF, Doody RS, Sairam R, Foster B, Liao TY. Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement Geriatr Cogn Disord. 2002;13:8-12.
Davis RN, Massman PJ, Doody RS. Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord. 2001;15:1-9.
Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, Gonzales N, Lai E, Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12:295-300.
Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427-33.
Doody RS, Massman P, Dunn JK. A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001;58:449-54.
Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-66.
Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481-8.
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-92.
Tangalos E, Doody R, Tariot P. Alzheimer's disease in long-term care: maximizing treatment options. J Am Med Dir Assoc. 2001;2:H17-20.
Doody RS. The issue of representation in brain research. Brain Cogn. 2000;42:26-8.
Doody RS. Mortality from pneumonia and hip fractures in patients with advanced dementia. Jama. 2000;284:2447; author reply 2448.
Doody RS, Azher SN, Haykal HA, Dunn JK, Liao T, Schneider L. Does APO epsilon4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000;69:668-71.
Hanna PA, Doody RS. Alien limb sign. Adv Neurol. 2000;82:135-45.
Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. Jama. 2000;283:1007-15.
Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000;10:195-203.
Doody RS. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology. 1999;45 Suppl 1:23-32.
Doody RS. Clinical benefits of a new piperidine-class AChE inhibitor. Eur Neuropsychopharmacol. 1999;9 Suppl 2:S69-77.
Doody RS. Therapeutic standards in Alzheimer disease. Alzheimer Dis Assoc Disord. 1999;13 Suppl 2:S20-6.
Doody RS, Strehlow SL, Massman PJ, Feher EP, Clark C, Roy JR. Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients. Alzheimer Dis Assoc Disord. 1999;13:53-9.
Doody RS, Vacca JL, Massman PJ, Liao TY. The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Arch Neurol. 1999;56:1133-7.
Doody R, Whitehouse PJ, Chen Q, Wang L, Wu Q, Rosser M, Xu XH. Alzheimer disease-related activities in China: a report from the International Working Group on the Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1998;12:263-5.
Doody RS, Massman PJ, Mawad M, Nance M. Cognitive consequences of subcortical magnetic resonance imaging changes in Alzheimer's disease: comparison to small vessel ischemic vascular dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1998;11:191-9.
Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021-31.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136-45.
Amaducci L, Baldereschi M, Doody R, Chandra V, Gaines AD. Cultural issues in the clinical diagnosis of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:19-21.
Antuono P, Doody R, Gilman S, Huff J, Scheltens P, Ueda K, Khachaturian ZS. Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:22-5.
Clark CM, Ewbank D, Lerner A, Doody R, Henderson VW, Panisset M, Morris JC, Fillenbaum GG, Heyman A. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1997;49:70-5.
Doody RS. Treatment of Alzheimer's disease. Neurologist. 1997;3:333-43.
Perkins P, Annegers JF, Doody RS, Cooke N, Aday L, Vernon SW. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology. 1997;49:44-50.
Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E, Morris JC, Rogers S, Sawada T. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:8-18.
Sabbagh MN, Lynn P, Jhingran S, Massman P, Villanueva-Meyer J, Olup J, Doody RS. Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1997;9:68-74.
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S22-32.
Strite D, Massman PJ, Cooke N, Doody RS. Neuropsychological asymmetry in Alzheimer's disease: verbal versus visuoconstructional deficits across stages of dementia. J Int Neuropsychol Soc. 1997;3:420-7.
Thal LJ, Carta A, Doody R, Leber P, Mohs R, Schneider L, Shimohama S, Silber C. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:46-9.
Kataki M, Winikates J, Kirkpatrick J, Doody RS. Longitudinal study of aphasia in Creutzfeldt-Jakob disease. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:284-7.
Massman PJ, Doody RS. Hemispheric asymmetry in Alzheimer's disease is apparent in motor functioning. J Clin Exp Neuropsychol. 1996;18:110-21.
Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology. 1996;46:720-6.
Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, Reisberg B, Schmitt FA. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol. 1996;9:176-80.
Doody RS, Massman P, Mahurin R, Law S. Positive and negative neuropsychiatric features in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1995;7:54-60.
Kotrla KJ, Chacko RC, Harper RG, Doody R. Clinical variables associated with psychosis in Alzheimer's disease. Am J Psychiatry. 1995;152:1377-9.
Kotrla KJ, Chacko RC, Harper RG, Jhingran S, Doody R. SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry. 1995;152:1470-5.
Shaibani A, Sabbagh M, Doody RS. Laughter and crying in neurologic disorders. Neuropsychiatry Neuropsychol Behav Neurol. 1994;7:243-50.
Doody RS. A reappraisal of localization theory with reference to aphasia. Part 2: Language theories from outside neurology. Brain Lang. 1993;44:327-48.
Doody RS. A reappraisal of localization theory with reference to aphasia. Part 1: Historical considerations. Brain Lang. 1993;44:296-326.
Doody RS. Sense and non-sense: dissemination and empiricism in practice. Ethos. 1992;20:220-9.
Doody RS, Hrachovy RA, Feher EP. Recurrent fluent aphasia associated with a seizure focus. Brain Lang. 1992;42:419-30.
Doody RS, Jankovic J. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992;55:806-10.
Feher EP, Mahurin RK, Doody RS, Cooke N, Sims J, Pirozzolo FJ. Establishing the limits of the Mini-Mental State. Examination of 'subtests'. Arch Neurol. 1992;49:87-92.
Doody RS. Aphasia as postmodern (anthropological) discourse. J Anthropol Res. 1991;47:285-303.
Feher EP, Doody RS, Whitehead J, Pirozzolo FJ. Progressive nonfluent aphasia with dementia: a case report. J Geriatr Psychiatry Neurol. 1991;4:236-40.
Doody RS, Rosenfield DB. Spasmodic dysphonia associated with palatal myoclonus. Ear Nose Throat J. 1990;69:829-32.
Feher EP, Doody R, Pirozzolo FJ, Appel SH. Mental status assessment of insight and judgment. Clin Geriatr Med. 1989;5:477-98.
Ornish D, Scherwitz LW, Doody RS, Kesten D, McLanahan SM, Brown SE, DePuey E, Sonnemaker R, Haynes C, Lester J, McAllister GK, Hall RJ, Burdine JA, Gotto AM, Jr. Effects of stress management training and dietary changes in treating ischemic heart disease. Jama. 1983;249:54-9.
Doody RS, Grose NP. The family medical history: assessing patient understanding of diabetes mellitus. Diabetes Care. 1981;4:285-8.

Poster Presentations
View Details | Collapse All | Expand All

Benge J, Balsis S, Geraci L, Massman P, Doody R. How well does the ADAS-cog measure the spectrum of Alzheimer's disease severity? An item response theory analysis. Neurology. 2009;72(11 Suppl 3):A247.
Doody R, Chan W, Pavlik V, Massman P, Darby E, Rountree S, Szigeti K. Age at onset and pre- morbid IQ influence early progression rates in AD. Neurology. 2009;72(11 Suppl 3):A478.
Cummings J, Doody RS, Gavrilova S, Sano M, Aisen P, Seely L, Hung D. Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia. 2008;4(4 Suppl):T770-1.
Doody RS, Ferris SH, Salloway S, Meuser TM, Murthy AK, Li MC, Goldman R. Interrater reliability between expert and nonexpert physicians in the assessment of amnestic MCI in the community setting. Alzheimer's & Dementia. 2008;4(4 Suppl):T263.
Doody RS, Gavrilova S, Thomas R, Aisen P, Bachurin S, Seely L, Hung D. Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study. Alzheimer's & Dementia. 2008;4(4 Suppl):T771.
Murthy AK, Schuff N, Suhy J, Doody RS, Goldman R. The effects of donepezil on Alzheimer's disease progression monitored by MRI. Alzheimer's & Dementia. 2008;4(4 Suppl):T55.
Rountree S, Pavlik V, Chan W, Doody RS. Persistent antidementia drug treatment and survival in an Alzheimer's disease (AD) cohort. Alzheimer's & Dementia. 2008;4(4 Suppl):T698-9.
Sparks L, Kivipelto M, Doody RS, Waters D, Jones RW, Feldman H, Pickering E, Hu X, Hall S, Breazna A, DeMicco DA, Hey-Hadavi J, Schindler RJ. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Effect of atorvastatin on Alzheimer's disease progression by APOE4 genotype. 2008 International Conference on Alzheimer's Disease (ICAD), Chicago, Illinois (July 26-31, 2008).
Doody RS, Ferris S, Salloway S, Meuser T, Murthy A, Li MC, Goldman R. Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnestic MCI in the community setting. Neurology. 2008;70(11 Suppl 1):A147.
Doody RS, Gavrilova S, Aisen P, Hirmand M, Sano M. Dimebon improves patient function and decreases caregiver assistance time in Alzheimer's disease: One-year clinical trial results. Neurology. 2008;70(11 Suppl 1):A98.
Ferris S, Doody R, Gavrilova S, Sano M, Aisen P, Seely L. Dimebon improves memory, orientation, language, and praxis in patients with mild to moderate Alzheimer's disease: Results of a one-year placebo-controlled study. Neurology. 2008;70(11 Suppl 1):A393-4.
Pavlik VN, Doody RS, Rountree SD, Darby EJ. Vitamin E use is associated with improved survival in an AD cohort. Neurology. 2008;70(11 Suppl 1):A146.
Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Gulley A, Doody RS. Exposure to anti-dementia drugs slows clinical progression of Alzheimer's disease (AD). Ann Neurol. 2007;62 Suppl 11:S55.
Doody R, Garrilova S, Sano M, Thomas R, Aisen P, Bachurin S, Seely L, Hung D. Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease. Alzheimer's & Dementia. 2007;3(3 Suppl):S199-200.
Jones R, Doody R, Sparks DL, Feldman H, Kivipelto M, Breazna A, Sovei M, DeMicco D, Hey-Hadavi J. Lipitor's effect in Alzheimer's dementia (LEADe) study: Baseline characteristics. Alzheimer's & Dementia. 2007;3(3 Suppl):S192-3.
Rountree SD, Pavlik VN, Chan W, Darby EJ, Doody RS. Clinical factors associated with the preprogression rate (PPR) in Alzheimer's disease (AD). Alzheimer's & Dementia. 2007;3(3 Suppl):S130.
Senanarong V, Hamphadungkit K, Poungvarin N, Cummings J, Doody R. The dementia and disability in Thai elderly project: Prevalence of mild cognitive impairment with one-year follow-up and the prevalence of dementia in community-dwelling Thai elderly. Alzheimer's & Dementia. 2007;3(3 Suppl):S178.
Doody R, Gavrilova S, Sano M, Thomas R, Aisen P, Seely L, Hung D. Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study. Neurology. 2007;68(12 Suppl 1):A353.
Feldman H, Sparks L, Doody R, Kivipelto M, Jones R, Sovel M, Breazna A, Hey-Hadavi J. Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe). Neurodegener Dis. 2007;4 Suppl 1:333.
Doody R, Pavlik V, Massman P, Rountree S, Waring S, Darby E, Chan W. Predicting progression and survival in Alzheimer's disease. Alzheimer's & Dementia. 2006;2(3 Suppl):S83.
Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS. Is functional decline necessary for a diagnosis of Alzheimer's disease? Alzheimer's & Dementia. 2006;2(3 Suppl):S263.
Rountree SD, Waring SC, Chan W, Darby EJ, Doody RS. Clinically presenting mild cognitive impairment (MCI): Variable presentations and their outcomes. Alzheimer's & Dementia. 2006;2(3 Suppl):S269.
Waring SC, Paranilam JM, Doody RS, Darby EJ, Massman PJ, Chan W. Preprogression rate, cardiovascular comorbidity, and survival in Alzheimer's disease. Alzheimer's & Dementia. 2006;2(3 Suppl):S159.
Doody R, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. Neurology. 2006;66(5 Suppl 2):A347.
Acharya D, Massman P, Doody R. Neuropsychological and demographic correlates of apraxia in a large cohort of Alzheimer's patients. Int J Neurosci. 2006;12 Supple S1:47.
Benge J, Massman P, Jenkins R, Thornton G, Doody R. Phonemic cued performance on the Boston Naming Test: Longitudinal change and its correlates in Alzheimer's disease. Int J Neurosci. 2006;12 Supple S1:55.
Jenkins R, Massman P, Benge J, Thornton G, Doody R. Naming improvement with phonemic cues: Which Alzheimer's patients benefit most? Int J Neurosci. 2006;12 Supple S1:51.
Thornton G, Massman P, Benge J, Jenkins R, Doody R. Category-letter fluency discrepancies in healthy older adults: Normative data and reliability. Int J Neurosci. 2006;12 Supple S1:192.
Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. Ann Neurol. 2005;58 Suppl 9:S49-50.
Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. Alzheimer's & Dementia. 2005;1(1 Suppl):S67.
Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, Galasko DR, Jin S, Levey AI, Petersen RC. Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis. Alzheimer's & Dementia. 2005;1(1 Suppl):S93.
Issa A, Rountree S, Waring S, Yeh S, Doody RS. Mild cognitive impairment types and their outcomes. Neurology. 2005;64(6 Suppl 1):A168.
Massman P, Doody RS. ADAS-Cog change rates in MMSE Strata relevant to clinical trials. Neurology. 2005;64(6 Suppl 1):A70.
Pavlik V, Doody RS, Massman P, Chan W, Yeh S. Relationship of premorbid IQ and education to progression of Alzheimer's disease. Neurology. 2005;64(6 Suppl 1):A317.
Schindler R, Corey-Bloom J, Doody R, Zhang R, Leni JR, Li H. Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day. European Journal of Neurology. 2004;11(Suppl 2):44.
Wirth Y, Doody RS, Schmitt FA, Mobius HJ, Stoffler A. Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. European Journal of Neurology. 2004;11(Suppl 2):193.
Doody R, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. Neurobiol Aging. 2004:25 Suppl 2:S469-70.
Massman P, Doody R. Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients. Neurobiol Aging. 2004;25 Suppl 2:S120.
Tariot P, Doody R, Peskind E, Winblad B, Reisberg B, Stoffler A, Graham S, McDonald S. Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary. Neurobiol Aging. 2004;25 Suppl 2:S99-100.
Wirth Y, Doody RS, Schmitt FA, Mobius HJ. Functional benefits of memantine treatment for patients with moderate to severe Alzhemier's disease. Neurobiol Aging. 2004;25 Suppl 2:S205.
Wirth Y, Doody R, Schmitt F, Mobius HJ, Stoffler A. Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease. Int J Neuropsychopharmacol. 2004;7 Suppl 2:S207.
Doody RS, Pratt RD, Perdomo CA, the Donepezil 307 and 308 vaD Study Groups. Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia. Neurology. 2003;60(5 Suppl 1):A412.
Ferris SH, Schmitt FA, Doody RS, Moebius H-J, Stoeffler A, Reisberg BJ. Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease. Neurology. 2003;60(5 Suppl 1):A414.
Clark C, Eubank D, Peskind E, Galasko D, Morris J, McKeel D, Farlow M, Weitlauf S, Quinn J, Kaye J, Knopman D, Arai H, Doody R, Decarli C, Leight S, Lee V, Xie S, Trojanowski J. How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses? Neurobiol Aging. 2002;23(1 Suppl):S274.
Doody RS. Pathogenesis and treatment strategies for selected therapies under development. Neurobiol Aging. 2002;23(1 Suppl):S144.
Reisberg B, Mobius H, Stoffler A, Schmitt F, Doody R, Ferris S. Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease. Neurobiol Aging. 2002;23(1 Suppl):S555.
Waring S, Doody RS. Survival in patients with dementia from a large multi ethnic population. Neuroepidemiology. 2002;21:211.
Doody RS, Kershaw P. The cognitive benefits of galantamine are sustained for at least 24 months: Results of a longterm extension trial in Alzheimer's disease. Neurology. 2001;56(8 Suppl 3):A456.
Waring S, Doody RS. Racial differences among patients with Alzheimer's disease from a large multi ethnic population. Neuroepidemiology. 2001;20:118.
Doody RS. Cholinesterase inhibitors: Benefits and limitations. Neurobiol Aging. 2000;21(1 Suppl):S8.
Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R. Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study. Neurology. 2000;54(Suppl 3):A415.
Sumaira R, Doody R, Lai EC. Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden. Neurology. 2000;54(Suppl 3):A417.
Doody R, Geldmacher DS, Pratt RD, Perdoma CA. Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety. Consult Pharm. 1999;14(10):1142.
Mohs R, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, Pratt R. Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study. Eur Neuropsychopharmacol. 1999;9 Suppl 5:S328.
Doody RS, Geldmacher DS, Pratt RD, Perdomo CA. Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration. J Neurol. 1999;246 Suppl 1:I52.
Azher S, Doody RS, Haykal H, Dunn JK, Liao T-Y. Does ApoE4 correlate with MRI changes in Alzheimer's disease? Neurology. 1999;52(Suppl 2):A366.
Doody RS, Pratt R, Perdomo C. Clinical benefits of donepezil: Results from a long-term phase III extension trial. Neurology. 1999;52(Suppl 2):A174.
Petit H, Doody RS, Pratt R. Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials. Eur Neuropsychopharmacol. 1998;8 Suppl 2:S274.
Doody RS, Clark C, Farlow M, Foster N, Gonzales N, Liao J, Lai E, Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients. Neurobiol Aging. 1998;19(Suppl 45):S303.
Kataki M, Doody RS, Liao J, Sims J. The presence of APO E4 does not influence rate of decline in Alzheimer's disease. Neurobiol Aging. 1998;19(Suppl 45):S137.
Doody RS. Current therapeutic standards in the treatment of Alzheimer's disease. Proceedings of the Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. 1998:32.
Rogers S, Mohs R, Friedhoff L, Doody RS. Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance? Proceedings of the Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. 1998:32.
Quinn JF, Benson DF, Clark C, Doody RS, Jagust W, Knopman D, Kaye J. Outcome measures in dementia trials-video CIBIC validity and reliability. Neurology. 1997;48(3):A233-A234.
Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil HCI (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study. American College of Neuropsychopharmacology (ACNP), 35th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996).
Kashani A, Doody RS, Wayner MJ, Phelix CF. Prevalence of uncontrolled hypertension in a population of Alzheimer's patients. International Behavioral Neuroscience Society (ISBN), 5th Annual Meeting in Cancun, Mexico (May 2-5, 1996).
Grundman M, Petersen R, Morris J, Ferris S, Sano M, Farlow M, Doody RS, Galasko D, Ernesto C, Thomas R, Thal L, the ADCS Cooperative Study. Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment. Neurology. 1996;46(2):A403.
Rogers S, Doody RS, Mohs R, Friedhoff L. E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial. Neurology. 1996;46(2):A217.
Sabbagh N, Smith RG, Lynn P, Doody RS, Appel SH, Killian JH. Pharmacologic evidence for autonomic psudomotor dysfunction in patients with Alzheimer's disease. Neurology. 1996;46(2):A162.
Olin J, Clark C, Doody RS, Schmitt F, Ferris S, Morris J, Reisberg B, Sneider L. Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials. Int J Neurosci. 1996;2:4.
Olin J, Schneider L, Clark C, Doody RS, Ferris S, Morris J, Reisberg B, Schmitt F. A new clinical global rating scale for Alzheimer's clinical trials. Gerontologist. 1995;35(2):63.
Doody RS, Young R, Lynn P, Cooke N, Rosenfield JE. Estrogen and psychomotor performance. J Neuropsychiatry Clin Neurosci. 1995;7(3):410.
Doody RS, Lynn P, Massman PJ. A calculated measure to predict rate of progression in Alzheimer's disease. Neurology. 1995;45(4 Suppl 4):A195.
Massman PJ, Doody RS. Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men. Int J Neurosci. 1995:145.
Doody RS, Massman PJ, Nance ML. Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD). Neurology. 1994;44(4 Suppl 2):A196.
Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs. Neurology. 1994;44(4 Suppl 2):A194.
Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease. Int J Neurosci. 1994:43.
Doody RS, Massman P. Dysfluency in the speech of AD patients. Ann Neurol. 1993;34(2):249.
Doody RS, Welsh K. Literacy and cognition in northern Thailand. Ann Neurol. 1993;34(2):249.
Dunn W, Doody RS, Gopnik M, Ashizawa T. Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia. Am J Hum Genet. 1993;53(Suppl):A1692.
Kotrla K, Chacko R, Jhingran S, Doody RS. Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease. American Psychiatric Association (APA), 146th Annual Meeting in San Francisco, California (May 22-27, 1993).
Massman P, Doody RS. Correlates of asymmetric motor speed in Alzheimer's disease. J Clin Exp Neuropsychol. 1993;15:31.
Massman P, Doody RS. Neuropsychological correlates of apraxia in Alzheimer's disease patients. Arch Clin Neuropsychol. 1992;8:249-50.
Doody RS. Positioning: Neurology and anthropology enabling practices. American Anthropological Association (AAA), 90th Annual Meeting in Chicago, Illinois (Nov. 20-24, 1991).
Doody RS, Strittmatter WJ, Jhingran S. Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia. Ann Neurol. 1991;30(2):249-50.
Feher E, Mahurin R, Doody RS, Cooke N, Simms J, Pirozzolo F. Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery. Ann Neurol. 1991;30(2):285-6.
Mahurin R, Feher E, Doody RS, Inbody S. Positive and negative psychiatric symptoms in Alzheimer's disease. Ann Neurol. 1991;30(2):239.
Doody RS, Jankovic J. The alien hand and related signs. Neurology. 1991;41(3 Suppl 1).
Doody RS. Sense and nonsense: Dissemination and empiricism in practice. American Anthropological Association (AAA), 89th Annual Meeting in New Orleans, Louisiana (Nov. 27 - Dec. 2, 1990).
Doody RS, Hrachovy RA. Recurrent posterior-type aphasia associated with a seizure focus. Electroencephalogr Clin Neurophysiol. 1991;79:28.
Feher E, Doody RS, Whitehead J, Priozzolo F. Progressive nonfluent aphasia. Neurology. 1990;40(4 Suppl 1).
Ornish DM, Scherwitz LW, Doody RS, et al. Effects of stress management and dietary changes in treating ischemic heart disease. American College of Cardiology (ACC), 31st Annual Scientific Session in Atlanta, Georgia (April 25-29, 1982).

Invited Speaker and Participant in Courses,
Collapse All | Expand All

Workshops, Symposia and Conferences

Key note speaker: Update on Alzheimer's Disease. Annual ADMDC/Alzheimer's Association Houston and SE Texas Chapter Community Program, Houston Museum of Natural Science/IMAX Theater, Houston, Texas. (Aug. 28, 2008)
Symposium chair: Alzheimer's Disease Therapeutics. International Conference on Alzheimer's Disease, Chicago, Ill. (July 30, 2008)
Invited speaker: Cholinesterase Inhibitors and Memantine: What are the Best Practices. Alzheimer's Disease Summit, Washington DC. (May 3, 2008)
Panelist: Research and Exploration. Rice Alumni Leaders, Rice University, Houston, Texas. (April 26, 2008)
LEADe Steering Committee: Late Breaking News Report: Lipitor's Effect in Alzheimer's Disease. American Academy of Neurology, Chicago, Ill. (April 16, 2008)
Invited speaker: Treatment in Alzheimer's Disease. Texas Public Health Association Conference, San Antonio, Texas. (March 7, 2008)
Chair: Clinical Relevance and Treatment Update in Mild Cognitive Impairment. International Hong Kong/Springfield Pan-Asia Symposium on Advances in Alzheimer's Disease Therapy. (Feb. 29, 2008)
Invited speaker: Latest Update on Alzheimer's Disease. Singapore General Hospital/Tan Tock Seng Hospital, Singapore. (Feb. 26, 2008)
Invited speaker: Progression of Alzheimer's Disease. Baylor Neurology Grand Rounds, Houston, Texas. (Feb. 22, 2008)
Invited speaker: Alzheimer's Disease Therapeutics. Schering-Plough, Kenilworth, N.J. (Feb. 8, 2008)
Invited speaker: Aspects of Memory. Sciencia Society, Rice University, Houston, Texas. (Jan. 15, 2008)
Invited speaker: Update on Alzheimer's Disease. ADMDC/Alzheimer's Association Annual Community Update, Houston, Texas. (Sept. 6, 2007)
Invited speaker: The Development of Alzheimer's Disease Therapies from the Laboratory to Practice. 2007 Texas Conference on Alzheimer's Disease and Care, Austin, Texas. (Aug. 23, 2007)
Co-Chair: Emerging Compounds. Alzheimer's Association International Conference on Prevention of Alzheimer's Disease, Washington, DC. (June 12, 2007)
Invited speaker: Update on Alzheimer's Disease. Baylor College of Medicine Neurology Grand Rounds, Houston, Texas. (Jan. 29, 2007)
Invited speaker: What is Really Known about Prevention and Treatment of Alzheimer's Disease. ADMDC/Alzheimer's Association Annual Community Update, Houston, Texas. (Aug. 31, 2006)
Co-Chair: 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain. (July 19, 2006)
Co-Chair: Neurologic Highlights: Dementia and Behavioral Neurology. American Academy of Neurology, San Diego, Calif. (April 6, 2006)
Invited speaker: Treating Alzheimer's Disease from a Specialist's Perspective. Central Texas Health Care System, Waco, Texas. (March 9, 2006)
Invited speaker: Alzheimer's Disease and Mild Cognitive Impairment. Texas Neurological Society, Austin, Texas. (Feb. 24, 2006)
Invited speaker: Update on Alzheimer's Disease. ADMDC/Alzheimer's Association Annual Community Update, Houston, Texas. (Sept. 19, 2005)
Co-Chair: Dementia and Aging. American Academy of Neurology, Miami, Fla. (April 13, 2005)
Invited speaker: Prevention and Treatment of Alzheimer's Disease. Baylor Methodist Neurology Grand Rounds, Houston, Texas. (March 21, 2005)
Invited speaker: Prevention and Treatment of Alzheimer's Disease. American Association of Clinical Psychiatrists, Houston, Texas. (March 18, 2005)
Invited speaker: Prevention and Treatment of Alzheimer's Disease. Texas Neurological Society, Austin, Texas. (Feb. 11, 2005)

Contact Information

Rachelle S. Doody, M.D., Ph.D.
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-7416
Fax: 713-798-5326
Email: